Nanomix Revenue and Competitors

Location

$49.3M

Total Funding

Estimated Revenue & Valuation

  • Nanomix's estimated annual revenue is currently $10.8M per year.(i)
  • Nanomix's estimated revenue per employee is $469,261
  • Nanomix's total funding is $49.3M.

Employee Data

  • Nanomix has 23 Employees.(i)
  • Nanomix grew their employee count by -47% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$19.1M76-3%N/AN/A
#2
$8M32-6%N/AN/A
#3
$5M20-9%N/AN/A
#4
$8.5M346%N/AN/A
#5
$5.3M21-9%N/AN/A
#6
$49.7M1980%N/AN/A
#7
$12M48N/AN/AN/A
#8
$8.5M3421%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$56.8M181-1%$199.1MN/A
Add Company

Nanomix, based in Emeryville, California, was founded in September 2000 by University of California, Berkeley physics professors Marvin Cohen and Alex Zettl to develop and commercialize nanotechnology breakthroughs in electronics and materials science. Today Nanomix’s team of scientists and engineers are developing hydrogen storage systems using nanostructured adsorbents and the first generation of commercial nanoelectronics. For more information, please go to www.nano.com .

keywords:N/A

$49.3M

Total Funding

23

Number of Employees

$10.8M

Revenue (est)

-47%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Nanomix News

2022-04-06 - Form 10-K NANOMIX Corp For: Dec 31

As of December 31, 2021 Nanomix Corporation had one class of securities registered under Section 12 of the Securities Exchange Act of 1934,...

2022-03-22 - Nanomix Appoints Vidur Sahney as Chief Operating Officer

Nanomix is the leader in the development of mobile point-of-care diagnostics with its Nanomix eLab platform and assays that provide rapid,...

2021-06-29 - Boston Therapeutics Announces $8.4 Million Convertible Placement in Conjunction with Nanomix Reverse Merger

Boston Therapeutics, Inc. (the “Company”) (OTCQB:BTHE) and merger partner Nanomix, Inc. (“Nanomix”), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that it has entered into a securities purchase agreement with accredited investors (the “Investors”) ...

2017-01-19 - A point-of-care company with handheld test device is taking on Abbott, Alere

Using a single patient’s blood sample, the device can provide analysis for lactate, PCT and C-Reactive protein to determine whether a patient has sepsis. “There isn’t anyone doing what we’re dong in sepsis or some of the infectious disease areas,” said David Ludvigson, CEO of Nanomix, in a rece ...

2014-01-31 - Nanomix Raises $12M

Nanomix, a Emeryville, Calif.-based developer of point-of-care diagnostic tests, raised approximately $12m in financing. A strategic corporate partner as well as unnamed existing investors participated in the round. The company intends to use the funds for development, registration of clinical ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.8M2315%N/A
#2
$2.3M23-18%N/A
#3
$3.7M24-14%N/A
#4
$2.5M250%N/A
#5
$4M26-7%N/A